Shoji, Hirokazu

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Rha, S. Y., Oh, D.-Y., Yañez, P., Bai, Y., Ryu, M.-H., Lee, J., Rivera, F., Alves, G. V., Garrido, M., Shiu, K.-K., et al. (2023) · The Lancet Oncology

Gastric Cancer Management and OutcomesCancer Immunotherapy and Biomarkers

Cited by 690

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.

Masuda, K., Shoji, H., Nagashima, K., Yamamoto, S., Ishikawa, M., Imazeki, H., Aoki, M., Miyamoto, T., Hirano, H., Honma, Y., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersGastric Cancer Management and Outcomes

Cited by 20

A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer

Osumi, H., Takashima, A., Ooki, A., Yoshinari, Y., Wakatsuki, T., Hirano, H., Nakayama, I., Okita, N., Sawada, R., Ouchi, K., et al. (2023) · Translational Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 16

Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study

Fukuda, K., Osumi, H., Yoshinami, Y., Ooki, A., Takashima, A., Wakatsuki, T., Hirano, H., Nakayama, I., Ouchi, K., Sawada, R., et al. (2024) · Journal of Cancer Research and Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 5